N-glycolyl-monosialodihexosyl-ganglioside (Neu5Gc-GM3, GM3(Neu5Gc), or NGcGM3) is an N-glycolyl variant of the ganglioside GM3 and an established tumor antigen. In humans, the typical GM3 is synthesized from lactosylceramide substrate via the addition of one sialic acid residue (Neu5Ac) by the enyzme lactosylceramide alpha-2,3-sialyltransferase (also called ST3GAL5 or GM3 synthase), which is encoded by the gene ST3GAL5. Humans cannot synthesize the N-glycolylated sialic acid Neu5Gc, thus that component's origin in Neu5Gc-GM3 and its addition is unclear, i.e. whether it is synthesized by enzymatic hydroxylation of this Neu5Ac residue to Neu5Gc or via addition of an existing Neu5Gc is unknown.
Anomalous presence in humans The enzyme which canonically hydroxylates Neu5Ac to Neu5Gc in deuterostomes is CMAH. In humans, it is pseudogene exhibiting a 92-bp frame-shifting deletion in a critical enzymatic binding pocket relative to the hominid ortholog, resulting from a human-specific Alu element insertion roughly 2.5 to 3 million years ago. This type of deletion process is well-documented in primates and known as retrotransposition-mediated deletion, and is unusually concentrated in recent human evolution. As a result, the enyzme is substantially truncated and completely inactive in modern humans, who cannot synthesize Neu5Gc by any known pathway and carry circulating antibodies against Neu5Gc-containing glycans and glycoconjugates, the affinities and antigenic moieties of which vary among individuals.
It has been suggested that subunit B of succinate dehydrogenase (mitochondrial respiratory complex II) may provide an alternative pathway for the synthesis of Neu5Gc-GM3.
Role in cancer biology As of 2026, the oncology literature suggests Neu5Gc-GM3 plays a mixed role in cancer biology, with respect to prognosis. It is known to predict tumor grade and proliferation and is highly associated with hypoxic conditions. Glycoconjugates containing Neu5Gc residues (including gangliosides like Neu5Gc-GM3) can bind with integral membrane receptors or be cleaved and released into the extracellular space, mediating immune function. Additionally, because Neu5Gc elicits humoral (or antibody-mediated) inflammation in humans, overabundance of Neu5Gc-GM3 may cause chronic inflammation and additional disease unrelated to actual tumor burden.
Applications in cancer therapy
Due to its genetically fixed absence in healthy adult human tissues and no documented pathway for its synthesis, the origin of Neu5Gc-GM3 in human cancers remains an open question. As a neoantigenic determinant in humans (i.e., a molecular structure, or epitope, not normally present thus unknown to the immune system), it is also an attractive target for cancer immunotherapy, particularly in chimeric antigen receptor T cells (CAR T cell) therapy. Studies of CAR T cells cultivated to target Neu5Gc-GM3 have shown excellent performance in specificity and binding affinity.
References